NCT06096779 2026-03-06
Kirros
Genentech, Inc.
Phase 2 Recruiting
Clinical Trials
25 trialsNCT05953337 2026-03-04
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
ABK Biomedical
Phase NA Active not recruiting
NCT05063565 2026-03-02
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT07377487 2026-02-20
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT06600321 2026-02-17
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Phase 1 Recruiting
NCT07191548 2025-10-10
LIVERMET-IRE
Angiodynamics, Inc.
Phase NA Not yet recruiting
NCT06352528 2025-10-06
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
Bristol-Myers Squibb
Phase 1 Completed
NCT05233098 2025-03-06
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
Completed
NCT06425198 2025-01-22
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
Bristol-Myers Squibb
Phase 1 Completed
NCT04926376 2024-11-29
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
ABK Biomedical
Phase NA Completed
NCT02301104 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Taiho Oncology, Inc.
Phase 1 Completed
NCT03814005 2024-09-05
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Phase 1 Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT00113113 2024-08-02
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT05053412 2024-08-02
HEPATIC
Helio Genomics
Completed
NCT02508467 2024-04-12
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
Blueprint Medicines Corporation
Phase 1 Completed
NCT02921828 2022-07-05
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Celgene
Completed
NCT04639115 2022-06-14
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
Celgene
Phase 1 Completed
NCT05084456 2021-10-19
Oral Docetaxel in Patients With Normal or Impaired Liver Function
Modra Pharmaceuticals
Phase 1 Withdrawn
NCT02868242 2020-03-02
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
Gilead Sciences
Phase 2 Completed
NCT01273493 2016-02-15
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
Janssen Research & Development, LLC
Phase 1 Completed
NCT00627042 2014-10-08
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
Eli Lilly and Company
Phase 2 Completed
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated
NCT00969410 2012-04-12
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00037804 2009-08-14
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
Pfizer
Phase 1 Completed